Retinitis pigmentosa: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• RPGR 2
• VEGF 0
• AMPK 0
• NRF2 0
• STAT3 0
• AKT 0
• APOE 0
• GLP-1 0
• HDAC 0
• PARP 0
• SGLT2 0
• TFEB 0
• TNF 0

248 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Tailored lipid nanoparticles for iontophoretic ocular drug delivery. (ODiN)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Repurposed Drug Neuroprotective Nanocarriers for Targeting Retinal Diseases (RENASCENT)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2027. szept.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Next generation versatile and effective AAV-mediated large gene delivery (NextGeneTx)

  Fondazione Telethon Ets· Roma, Olaszország· EU contribution 1 500 000 EUR· until 2030. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  European Training Program to Understand, Diagnose and Treat Autosomal Dominant Retinal Diseases (ProgRet)

  Universiteit Gent· Gent, Belgium· EU contribution 2 626 200 EUR· until 2027. dec.· 10 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Targeting RNA as an approach for treating retinal disease (RETORNA)

  Fundacion Universidad Catolica de Valencia San Vicente Martir· Valencia, Spanyolország· EU contribution 2 568 426 EUR· until 2027. jan.· 6 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 6 running projects, newest first. Listed amounts together: 9,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  CNGB1 and Allied Disorders

  NCT04639635· Columbia University· Frissítve: 2026. ápr. 13.

  “IRB renewal lapsed”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)

  NCT05841862· 2C Tech Corp· Frissítve: 2025. jún. 12.

  “Lack of funding.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Natural History Study to Evaluate Functional and Anatomical Progression in Retinitis Pigmentosa

  NCT04558983· Johns Hopkins University· Frissítve: 2024. dec. 27.

  “The study stopped because patients dropped out of the study to participate in the interventional trials. With interventional trials present there is very little interest in participating in a Natural Histoy study.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO)

  NCT04120883· University of Michigan· Frissítve: 2024. okt. 26.

  “Unable to recruit additional participants after multiple extensions to planned enrollment period.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

  NCT05392751· Endogena Therapeutics, Inc· Frissítve: 2024. okt. 15.

  “Study terminated by the Sponsor. All study participants completed at least 12 months of safety follow-up instead of 24 mo. The reason for earlier termination was due to a corporate decision; not any safety concerns of EA-2353.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa

  NCT03629899· Wills Eye· Frissítve: 2019. máj. 10.

  “unavailability of the investigational device”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  PMCF Study for Partial Vision Restoration Using the Subretinal Implant RETINA IMPLANT Alpha AMS

  NCT02588430· Retina Implant AG· Frissítve: 2019. ápr. 19.

  “Manufacturer of the investigational device has ceased all business activities”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment

  NCT07341763· University of Waterloo· Forrás

• Rate of Progression in EYS Related Retinal Degeneration

  NCT04127006· Jaeb Center for Health Research· Forrás

• Rate of Progression in USH2A-related Retinal Degeneration

  NCT03146078· Jaeb Center for Health Research· Forrás

• Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

  NCT05589714· Jaeb Center for Health Research· Forrás

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Forrás

• Oral N-acetylcysteine for Retinitis Pigmentosa

  NCT05537220· Johns Hopkins University· Forrás

• Adaptive Optics Imaging of Outer Retinal Diseases

  NCT05355415· Food and Drug Administration (FDA)· Forrás

• Natural History Study of Patients With EYS-Associated RP

  NCT07228793· Sensor Technology for Deafblind· Forrás

• North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

  NCT01694940· Columbia University· Forrás

• Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

  NCT04765345· Jaeb Center for Health Research· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 1
• Organoids 11
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 7
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 19
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 1
• Immunohistochemistry 9
• Magnetic Resonance Imaging 3
• Machine Learning 1
• Deep Learning 2
• Cohort Studies 5
• Genome-Wide Association Study 5

• Autosomal Recessive RDH12-Leber Congenital Amaurosis Retinal Organoids Suggest Phospholipid Pathway Dysregulation.

  Int J Mol Sci, 2026. okt.

• Cell-autonomous restoration of splicing homeostasis and RP11 phenotype in patient-derived RPE and retinal organoids by PRPF31.AAV gene therapy.

  Nat Commun, 2026. szept.

• CLRN1 Variants in Müller Cells Cause Mitochondrial Dysfunction in USH3A Retinal Organoids.

  CNS Neurosci Ther, 2026. aug.

• Loss of INPP5E affects photoreceptor outer segment membrane biogenesis in iPSC-derived human retinal organoids.

  J Cell Sci, 2026. júl.

• Retinal organoids and stem cell therapy for vision restoration: current progress, persistent challenges, and future directions.

  Int Immunopharmacol, 2026. júl.

• Single-cell analysis reveals impaired Müller glia-mediated intercellular communication and photoreceptor pathology in USH1C retinal organoids.

  Cell Mol Life Sci, 2026. júl.

• Cell-type-focused compound screen in human organoids reveals CK1 inhibition protects cone photoreceptors from death.

  Neuron, 2026. márc.

• KCNV2-Deficient Retinal Organoid Model of Cone Dystrophy-In Vitro Screening for AAV Gene Replacement Therapy.

  Int J Mol Sci, 2025. dec.

• Application of Machine Learning to Discriminate Photoreceptor Cell Species in Xenotransplanted Chimeric Retinas.

  Clin Transl Sci, 2025. dec.

• Connecting cilium, stress response, and proteostasis abnormalities inform variant and therapy assessment in RPGRIP1 retinal organoids.

  Stem Cell Reports, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.